No Data
Spyre Therapeutics(SYRE.US) Director Sells US$5.95 Million in Common Stock
$Spyre Therapeutics(SYRE.US)$ Director HENDERSON MICHAEL THOMAS sold 80,000 shares of common stock on May 8, 2026 at an average price of $74.4 for a total value of $5.95 million.Source: Announcement
Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $97
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $107
Citigroup Maintains Buy on Spyre Therapeutics, Raises Price Target to $97
Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $107
Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $95